These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 19917876)

  • 1. Aliskiren monotherapy does not cause paradoxical blood pressure rises: meta-analysis of data from 8 clinical trials.
    Stanton AV; Gradman AH; Schmieder RE; Nussberger J; Sarangapani R; Prescott MF
    Hypertension; 2010 Jan; 55(1):54-60. PubMed ID: 19917876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.
    O'Brien E; Barton J; Nussberger J; Mulcahy D; Jensen C; Dicker P; Stanton A
    Hypertension; 2007 Feb; 49(2):276-84. PubMed ID: 17159081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct Renin inhibition with aliskiren in obese patients with arterial hypertension.
    Jordan J; Engeli S; Boye SW; Le Breton S; Keefe DL
    Hypertension; 2007 May; 49(5):1047-55. PubMed ID: 17353513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficacy of aliskiren monotherapy and ramipril monotherapy in patients with stage 2 systolic hypertension: subgroup analysis of a double-blind, active comparator trial.
    Andersen K; Weinberger MH; Egan B; Constance CM; Wright M; Lukashevich V; Keefe DL
    Cardiovasc Ther; 2010 Dec; 28(6):344-9. PubMed ID: 20406241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aliskiren: an oral renin inhibitor for the treatment of hypertension.
    Lam S; Choy M
    Cardiol Rev; 2007; 15(6):316-23. PubMed ID: 18090068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood pressure lowering efficacy of renin inhibitors for primary hypertension.
    Musini VM; Lawrence KA; Fortin PM; Bassett K; Wright JM
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD007066. PubMed ID: 28379619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension.
    Uresin Y; Taylor AA; Kilo C; Tschöpe D; Santonastaso M; Ibram G; Fang H; Satlin A
    J Renin Angiotensin Aldosterone Syst; 2007 Dec; 8(4):190-8. PubMed ID: 18205098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan.
    Pool JL; Schmieder RE; Azizi M; Aldigier JC; Januszewicz A; Zidek W; Chiang Y; Satlin A
    Am J Hypertens; 2007 Jan; 20(1):11-20. PubMed ID: 17198906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension.
    Andersen K; Weinberger MH; Constance CM; Ali MA; Jin J; Prescott MF; Keefe DL
    J Renin Angiotensin Aldosterone Syst; 2009 Sep; 10(3):157-67. PubMed ID: 19617271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aliskiren monotherapy results in the greatest and the least blood pressure lowering in patients with high- and low-baseline PRA levels, respectively.
    Stanton AV; Dicker P; O'Brien ET
    Am J Hypertens; 2009 Sep; 22(9):954-7. PubMed ID: 19556972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study.
    Palatini P; Jung W; Shlyakhto E; Botha J; Bush C; Keefe DL
    J Hum Hypertens; 2010 Feb; 24(2):93-103. PubMed ID: 19458624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy, safety and tolerability of aliskiren, a direct renin inhibitor, in women with hypertension: a pooled analysis of eight studies.
    Gradman AH; Weir MR; Wright M; Bush CA; Keefe DL
    J Hum Hypertens; 2010 Nov; 24(11):721-9. PubMed ID: 20200550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness.
    Sealey JE; Laragh JH
    Am J Hypertens; 2007 May; 20(5):587-97. PubMed ID: 17485026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial.
    Duprez DA; Munger MA; Botha J; Keefe DL; Charney AN
    J Hum Hypertens; 2010 Sep; 24(9):600-8. PubMed ID: 20033075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide.
    Villamil A; Chrysant SG; Calhoun D; Schober B; Hsu H; Matrisciano-Dimichino L; Zhang J
    J Hypertens; 2007 Jan; 25(1):217-26. PubMed ID: 17143194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren.
    Stanton A; Jensen C; Nussberger J; O'Brien E
    Hypertension; 2003 Dec; 42(6):1137-43. PubMed ID: 14597641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K
    Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct inhibition of renin as a cardiovascular pharmacotherapy: focus on aliskiren.
    Sepehrdad R; Frishman WH; Stier CT; Sica DA
    Cardiol Rev; 2007; 15(5):242-56. PubMed ID: 17700383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood pressure lowering efficacy of renin inhibitors for primary hypertension.
    Musini VM; Fortin PM; Bassett K; Wright JM
    Cochrane Database Syst Rev; 2008 Oct; (4):CD007066. PubMed ID: 18843743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients.
    Gradman AH; Schmieder RE; Lins RL; Nussberger J; Chiang Y; Bedigian MP
    Circulation; 2005 Mar; 111(8):1012-8. PubMed ID: 15723979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.